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Abstract
Human podoplanin (hPDPN), a platelet aggregation- inducing transmembrane 
glycoprotein, is expressed in different types of tumors, and it binds to C- type 
lectin- like receptor 2 (CLEC- 2). The overexpression of hPDPN is involved in 
invasion and metastasis. Anti- hPDPN monoclonal antibodies (mAbs) such as 
NZ- 1 have shown antitumor and antimetastatic activities by binding to the 
platelet aggregation- stimulating (PLAG) domain of hPDPN. Recently, we de-
veloped a novel mouse anti-hPDPN mAb, LpMab- 2, using the cancer- specific 
mAb (CasMab) technology. In this study we developed chLpMab- 2, a human–
mouse chimeric anti- hPDPN antibody, derived from LpMab- 2. chLpMab- 2 was 
produced using fucosyltransferase 8- knockout (KO) Chinese hamster ovary 
(CHO)- S cell lines. By flow cytometry, chLpMab- 2 reacted with hPDPN- 
expressing cancer cell lines including glioblastomas, mesotheliomas, and lung 
cancers. However, it showed low reaction with normal cell lines such as lym-
phatic endothelial and renal epithelial cells. Moreover, chLpMab- 2 exhibited 
high antibody- dependent cellular cytotoxicity (ADCC) against PDPN- expressing 
cells, despite its low complement- dependent cytotoxicity. Furthermore, treatment 
with chLpMab- 2 abolished tumor growth in xenograft models of CHO/hPDPN, 
indicating that chLpMab- 2 suppressed tumor development via ADCC. In con-
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Introduction
Human podoplanin (hPDPN), also known as hT1α, hAg-
grus, or gp36, is expressed in many types of cancers, 
such as malignant brain tumors, malignant mesotheliomas, 
lung cancers, esophageal cancers, testicular tumors, bladder 
cancers, osteosarcomas, and fibrosarcomas [1–15]. hPDPN 
expression is observed only in squamous cell carcinomas 
of lung and esophageal cancers, indicating that hPDPN 
exhibits histological type- specific expression. The expres-
sion of hPDPN in cancer- associated fibroblasts contributes 
to a poor prognosis [16–21]. C- type lectin- like receptor 
2 (CLEC- 2) is an endogenous receptor of hPDPN [22, 
23]. CLEC- 2 binds to hPDPN through residues Glu47 
and Asp48 within its platelet aggregation- stimulating 
(PLAG) domain and to α- 2,6- linked sialic acid, which is 
attached to Thr52 [24].
Membrane proteins could be targeted by antibody- based 
therapy if (1) they possess cancer- specific mutations outside 
the membrane [25], (2) they are overexpressed in cancers 
rather than in normal tissues [26–28], or (3) they are 
posttranslationally modified by phosphorylation or glyco-
sylation [29, 30]. Although many anti- hPDPN monoclonal 
antibodies (mAbs) are commercially available, most of 
them react with the N- terminus of hPDPN, and they do 
not fulfill the above- mentioned criteria [6, 31–35]. hPDPN 
is highly expressed in normal lymphatic endothelial cells 
(LECs) and normal lung type- I alveolar cells at the same 
level as in cancer cells. We previously produced a rat 
anti- hPDPN mAb (NZ- 1), which detects hPDPN with 
high specificity and sensitivity [6, 10, 31]. NZ- 1 is effi-
ciently internalized by glioma cell lines and accumulates 
in tumors in vivo; therefore, it has been suggested to be 
a suitable candidate for therapy against malignant gliomas 
[5, 10]. Moreover, NZ- 1 inhibits tumor cell- induced platelet 
aggregation and tumor metastasis [23]. NZ- 1 mediates 
antibody- dependent cellular cytotoxicity (ADCC) and 
complement- dependent cytotoxicity (CDC) against tumor 
cells that express hPDPN [36]. Furthermore, human–rat 
chimeric antibodies, such as NZ- 8 and NZ- 12, exhibit 
high ADCC and CDC in vitro, and they show very high 
antitumor activities and neutralizing capabilities [36, 37]. 
Nevertheless, these chimeric mAbs are not cancer- specific; 
therefore, cancer- specific anti- hPDPN chimeric or human-
ized antibodies should be developed to prevent unfavorable 
side effects.
We have developed the original technology to produce 
cancer- specific mAbs (CasMabs) against hPDPN [29, 
38–46]. The established LpMab- 2 recognized the aberrant 
O- glycosylation and Thr55–Leu64 peptide of hPDPN [29]. 
LpMab- 2 reacted with hPDPN- expressing cancer cells but 
not with normal cells, as shown by flow cytometry and 
immunohistochemistry. Therefore, LpMab- 2 is an 
anti- hPDPN CasMab that can be used for molecular- 
targeted therapy against hPDPN- expressing cancers. In 
immunohistochemistry, less than 10% of hPDPN- 
expressing cancer cells were recognized by LpMab- 2. In 
contrast, another anti- hPDPN mAb LpMab- 7 reacted with 
both hPDPN- expressing cancer cells and normal cells [42]. 
We identified the minimum epitope of LpMab- 7 as Arg79–
Leu83 of hPDPN using ELISA, Western- blot, and flow 
cytometry. We further produced a human–mouse chimeric 
anti- hPDPN mAb, chLpMab- 7 [40]. chLpMab-7 showed 
ADCC and CDC, and inhibited the growth of hPDPN- 
expressing tumors in vivo.
In this study, we developed and characterized chLpMab-




LpMab- 2, a mouse anti- hPDPN mAb (IgG1, kappa), was 
developed as previously described [29]. Human IgG was 
purchased from Beckman Coulter, Inc. (Fullerton, CA). To 
generate human–mouse chimeric anti- hPDPN (chLpMab- 2), 
appropriate VH and VL cDNAs of mouse LpMab- 2 and CH 
and CL of human IgG1 were subcloned into pCAG- Ble and 
pCAG- Neo vectors (Wako Pure Chemical Industries, Ltd., 
Osaka, Japan), respectively. CHO- S/fucosyltransferase 8 
(FUT8)- KO (PDIS- 5) cell lines were generated by transfect-
ing CRISPR/Cas9 plasmids that targeted FUT8 (Target ID: 
HS0000547010; Sigma- Aldrich Corp., St. Louis, MO) into 
CHO- S cells (Thermo Fisher Scientific Inc., Waltham, MA) 
using a Gene Pulser Xcell electroporation system. PDIS- 5 
cells were screened using Aleuria aurantia lectin. Antibody 
expression vectors were transfected into PDIS- 5 using the 
Lipofectamine LTX reagent (Thermo Fisher Scientific Inc.). 
Stable transfectants of PDIS- 5/chLpMab- 2 were selected by 
cultivating the transfectants in a medium containing 0.5 mg/
mL of both geneticin and zeocin (InvivoGen, San Diego, 
CA). PDIS- 5/chLpMab- 2 cells were cultivated in CHO- S- 
SFM II medium (Thermo Fisher Scientific Inc.). chLpMab-2 
was purified using Protein G- Sepharose (GE healthcare Bio- 
Sciences, Pittsburgh, PA).
Cell lines
The cell lines LN229, HEK- 293T, NCI- H226, Met- 5A, 
Chinese hamster ovary (CHO)- K1, and P3U1 were obtained 
from the American Type Culture Collection (Manassas, 
VA). The LN319 cell line was provided by Prof. Kazuhiko 
Mishima (Saitama Medical University, Saitama, Japan) [47]. 
Human LECs and PC- 10 cells were purchased from 
Cambrex Corp. (Walkersville, MD) and Immuno- Biological 
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Laboratories Co., Ltd. (Gunma, Japan), respectively. LN229 
and CHO- K1 cells were transfected with hPDPN plasmids 
using Lipofectamine 2000 (Thermo Fisher Scientific Inc.) 
according to the manufacturer’s instructions [29]. The 
LN319/hPDPN- KO cell line (PDIS- 6) was generated by 
transfection using CRISPR/Cas9 plasmids (Target ID: 
HS0000333287) that targeted PDPN (Sigma- Aldrich, St. 
Louis, MO), as previously described [48]. The cell lines 
CHO- S/GnT- 1- KO (PDIS- 9) and CHO- S/SLC35A1- KO 
(PDIS- 14) were generated by transfecting TALEN and 
CRISPR/Cas9 plasmids, respectively. The former plasmid- 
targeted hsMgat1 (Wako Pure Chemical Industries Ltd.) 
and the latter targeted SLC35A1 (Target ID: HS0000168432; 
Sigma- Aldrich) [49].
The CHO- K1, CHO/hPDPN, NCI- H226, PC- 10, and P3U1 
cells were cultured in RPMI 1640 medium containing 
L- glutamine (Nacalai Tesque, Inc., Kyoto, Japan). The LN229, 
LN229/hPDPN, LN319, HEK- 293T, and PDIS- 6 cells were 
cultured at 37°C in a humidified atmosphere containing 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 
L- glutamine (Nacalai Tesque, Inc.) and 10% heat- inactivated 
fetal bovine serum (FBS) (Thermo Fisher Scientific Inc.). 
CHO- S, PDIS- 9, and PDIS- 14 were cultured in CHO- S- 
SFMII medium (Thermo Fisher Scientific Inc.). LECs were 
cultured in the endothelial cell medium EGM- 2MV sup-
plemented with 5% FBS (Cambrex Corp.). All media con-
tained 100 U/mL of penicillin, 100 μg/mL of streptomycin, 
and 25 μg/mL of amphotericin B (Nacalai Tesque, Inc.).
Flow cytometry
The cell lines were harvested after brief exposure to 0.25% 
trypsin/1 mmol/L EDTA (Nacalai Tesque, Inc.). After 
washing with 0.1% BSA in PBS, the cells were treated 
with primary mAbs for 30 min at 4°C, followed by treat-
ment with FITC-labeled goat anti-human IgG (Thermo 
Fisher Scientific Inc.). Fluorescence data were acquired 
using Cell Analyzer EC800 (Sony Corp., Tokyo, Japan).
Preparation of effector cells
Effector cells were prepared as previously described [9]. 
Human peripheral blood mononuclear cells (MNCs) were 
obtained from leukocytes, which were separated from the 
peripheral blood of healthy donors. The study with human 
subjects was approved by the Ethics Committee of 
Tokushima University.
ADCC
ADCC was determined with the 51Cr release assay [9]. 
Target cells were incubated with 0.1 μCi of 51Cr- sodium 
chromate at 37°C for 1 h. After washing three times with 
RPMI 1640 supplemented with 10% FBS, 51Cr- labeled target 
cells were seeded in 96- well plates in triplicate. Human 
peripheral blood MNCs and chLpMab- 2 or control human 
IgG were added to the cells. After 6 h of incubation, 51Cr 
released from cells into the supernatant (100 μL) was meas-
ured using a gamma counter (PerkinElmer, Waltham, MA). 
The percentage of cytotoxicity was calculated using the 
following formula: % specific lysis = (E − S)/(M − S) × 
100, where E is the release in the test sample, S is the 
spontaneous release, and M is the maximum release.
CDC
CDC was evaluated by the 51Cr release assay as previously 
described [9]. The CHO/hPDPN cells (target cells) were 
incubated with 51Cr- sodium chromate (0.1 μCi) for 1 h 
at 37°C. After incubation, the cells were washed with RPMI 
1640 supplemented with 10% FBS. The 51Cr- labeled cells 
were incubated with baby rabbit complement (Cedarlane, 
Ontario, Canada) at a dilution of 1:32 and chLpMab- 2 
(0.01–10 μg/mL) or control human IgG (0.01–10 μg/mL) 
for 3 h in 96- well plates. After incubation, 51Cr in the 
supernatant was measured using a gamma counter. The 
percentage of cytotoxicity was calculated using the follow-
ing formula: % specific lysis = (E − S)/(M − S) × 100, 
where E is the release in the test sample, S is the spon-
taneous release, and M is the maximum release.
Antitumor activity of anti- hPDPN antibodies
CHO/hPDPN cells were trypsinized and washed with PBS. 
The cell density was adjusted with PBS to 5.0 × 107 cells/
mL, and 100 μL/animal of the cell suspension was sub-
cutaneously inoculated into BALB/c nude mice. After 
1 day, 100 μL of 1 mg/mL of chLpMab- 2 and human 
IgG were injected into the peritoneal cavity of mice, once 
a week for 4 weeks (control group, n = 6; chLpMab- 2 
group, n = 6). Human NK cells (5.0 × 105 cells, Takara 
Bio Inc., Shiga, Japan) were injected around the tumors 
4 and 11 days after cell inoculation. The tumor diameter 
was measured every 3–4 days and was calculated using 
the following formula: volume = W2 × L/2, where W is 
the short diameter and L is the long diameter. The mice 
were euthanized 21 days after cell implantation.
Statistical analysis
All data were expressed as means ± SEMs. Student’s  t- test, 
Mann–Whitney U- test, one- way ANOVA followed by 
Tukey–Kramer multiple comparisons, and two- way 
ANOVA were performed as appropriate. P values less than 
0.05 were considered to be statistically significant. All 
statistical tests were two- sided.
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Results
Production of chLpMab- 2
We developed chLpMab- 2 from a mouse mAb, LpMab- 2. 
chLpMab- 2 reacted with LN229/hPDPN cells as revealed 
by flow cytometry (Fig. 1A). chLpMab- 2 detected 
endogenous hPDPN in glioblastoma cell line LN319 and 
not in the LN319/hPDPN- KO cells (PDIS- 6) (Fig. 1B). 
Our results showed that chLpMab- 2 was specific against 
hPDPN.
Figure 1. Flow cytometric analysis using chLpMab-2 to detect 
hPDPN expression. (A) LN229 and LN229/hPDPN cells were treated 
with chLpMab- 2 (1 μg/mL, red), chLpMab- 7 (1 μg/mL, blue), and PBS 
(black) for 30 min at 4°C, followed by treatment with antihuman IgG- 
FITC. (B) LN319 and LN319/hPDPN- KO cells (PDIS- 6) were treated with 
chLpMab- 2 (1 μg/mL, red), chLpMab- 7 (1 μg/mL, blue), and PBS (black) 
for 30 min at 4°C, followed by treatment with antihuman IgG- FITC. 
Fluorescence data were collected using Cell Analyzer EC800.
Figure 2. Flow cytometric analysis using chLpMab-2 to detect 
PDPN expression in human cancer and normal cells. (A) Human 
cancer cell lines such as lung squamous cell carcinoma (PC- 10) and 
mesothelioma (NCI- H226) were treated with chLpMab- 2 (1 μg/mL, red), 
chLpMab- 7 (1 μg/mL, blue), and PBS (black) for 30 min at 4°C, followed 
by treatment with antihuman IgG- FITC. (B) Normal human cell lines 
such as mesothelial cells (Met5A) and renal epithelial cells (HEK- 293T) 
were treated with chLpMab- 2 (1 μg/mL, red), chLpMab- 7 (1 μg/mL, 
blue), and PBS (black) for 30 min at 4°C, followed by treatment with 
antihuman IgG- FITC. Fluorescence data were acquired using Cell 
Analyzer EC800.
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Flow cytometric analyses of chLpMab- 2 in 
cancer and normal cell lines
hPDPN is expressed in cancers such as brain tumors and 
mesotheliomas. By flow cytometry, chLpMab- 2 detected 
endogenous PDPN in human cancer cell lines such as 
PC- 10 of lung squamous cell carcinoma and NCI- H226 
of mesothelioma (Fig. 2A). A positive control, chLpMab- 7, 
detected PDPN expression in two cancer cell lines (Fig. 2A). 
Because of low hPDPN expression in NCI- H226 [29], 
the reaction of chLpMab- 2 against NCI- H226 was much 
lower than that of chLpMab- 7. In contrast, chLpMab- 2 
failed to detect the expression of hPDPN in normal cells 
such as renal epithelial cells (HEK- 293T) and the meso-
thelial cell line Met- 5A (Fig. 2B). However, chLpMab- 7 
reacted with these cells (Fig. 2B), indicating that chLpMab- 2 
was cancer- specific. These results are consistent with those 
of our previous study [29].
Characterization of chLpMab- 2 using glycan- 
deficient cell lines
Previous studies have shown that hPDPN is O- glycosylated 
and not N- glycosylated [6, 24, 50–52]. We used a GnT- 
1- KO cell line (CHO- S/GnT- 1- KO, PDIS- 9) and a CMP- 
sialic acid transporter (SLC35A1)- KO cell line (CHO- S/
SLC35A1- KO, PDIS- 14) [49] to characterize chLpMab- 2. 
As shown in Figure 3B, chLpMab- 7 reacted with CHO- S/
hPDPN, PDIS- 9/hPDPN, and PDIS- 14/hPDPN cells trans-
fected with the hPDPN expression vector. In contrast, 
chLpMab- 2 reacted with the CHO- S/hPDPN and PDIS- 9/
hPDPN cells and not with the PDIS- 14/hPDPN cells 
(Fig. 3A). This result agrees with that of our previous 
study [29] that the epitope of chLpMab- 2 includes sialic 
acid.
ADCC and CDC
LpMab- 2 was previously determined to belong to the 
mouse IgG1 subclass that failed to induce ADCC and 
CDC [29]. Therefore, in this study, we converted LpMab- 2 
to chLpMab- 2 of human IgG1 to study ADCC and CDC 
[40]. As shown in Figure 4A, chLpMab- 2 showed ADCC 
against the LN319, PC- 10, and NCI- H226 cell lines. The 
CHO/hPDPN and CHO- K1 cells were used to study the 
specificity of chLpMab- 2 against hPDPN. As shown in 
Figure 4B, chLpMab- 2 showed ADCC against the CHO/
hPDPN cells and not against the hPDPN- negative CHO- 
K1 cells. Furthermore, chLpMab- 2- induced ADCC against 
CHO/hPDPN in a dose- dependent manner (Fig. 5A). In 
contrast, chLpMab- 2 shows weak CDC against CHO/
hPDPN cells (Fig. 5B) and against LN319, PC- 10, and 
NCI- H226 cell lines (data not shown).
Figure 3. Flow cytometric analysis using chLpMab- 2 to detect hPDPN expression in N- glycan and sialic acid- deficient cells. CHO- S, CHO- S/hPDPN, 
PDIS- 9/hPDPN, and PDIS- 14/hPDPN cells were reacted with chLpMab- 2 (A, 1 μg/mL; red), chLpMab- 7 (B, 1 μg/mL; blue), and PBS (black) for 30 min 
at 4°C, followed by treatment with antihuman IgG- FITC. Fluorescence data were acquired using Cell Analyzer EC800.
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Antitumor activity of chLpMab- 2
To study the antitumor activity of chLpMab- 2 on primary 
tumor growth in vivo, the CHO/hPDPN cells were sub-
cutaneously implanted into the flanks of nude mice. The 
LN319, PC- 10, and NCI- H226 cells were not tested because 
they were not suitable for xenograft models. chLpMab- 2 
and control human IgG were injected into the peritoneal 
cavity of mice, once weekly for 4 weeks (n = 6 each), 
and human NK cells were injected twice around the tumors. 
Tumor formation was observed in mice from the control 
and treated groups. However, chLpMab- 2 significantly 
reduced tumor development compared with control human 
IgG (Fig. 6A and B). The tumor volume was significantly 
reduced by chLpMab- 2 treatment on day 15, 18, and 21 
(Fig. 6C). These results indicate that the administration 
of chLpMab- 2 with the NK cells inhibited the primary 
tumor growth of the CHO/hPDPN cells in vivo.
Discussion
We previously produced LpMab- 2 (mouse IgG1, kappa), 
one of the CasMabs against hPDPN [29]. LpMab- 2 
recognized not only the Thr55–Leu64 peptide of hPDPN 
but also an aberrant O- glycosylated hPDPN, which is 
attached to Thr55 or Ser56 of hPDPN [48]. LpMab- 2 
reacted with hPDPN- expressing cancer cells and not with 
normal cells, as revealed by flow cytometry and immu-
nohistochemistry [29]; therefore, LpMab- 2 is an anti- 
hPDPN CasMab that is potentially advantageous for 
antibody- based molecular- targeted therapy against hPDPN- 
expressing cancers. However, LpMab- 2 is a mouse IgG1; 
therefore, it cannot be used to study ADCC and CDC 
against hPDPN- expressing cancers.
To our knowledge, herein we developed the first cancer- 
specific human–mouse chimeric anti- hPDPN antibody 
(chLpMab- 2) from LpMab- 2. Previously, we had developed 
a human–mouse chimeric anti- hPDPN antibody 
Figure 4. ADCC of chLpMab- 2 against hPDPN- expressing cell lines. (A) 
ADCC of chLpMab- 2 using human MNCs against (A) LN319, PC- 10, 
and NCI- H226 and (B) CHO and CHO/hPDPN were evaluated by a 6- h 
51Cr release assay in the presence of 1 μg/mL of antibody with an E/T 
ratio of 100. **P < 0.01
Figure 5. ADCC and complement- dependent cytotoxicity (CDC) of 
chLpMab- 2 against CHO/hPDPN cells. (A) ADCC of chLpMab- 2 using 
human MNCs against CHO/hPDPN was evaluated by a 6- h 51Cr release 
assay in the presence of 0.01–10 μg/mL of antibody with an E/T ratio of 
100. (B) CDC of chLpMab- 2 using baby rabbit complement against 
CHO/hPDPN was evaluated by 51Cr release assay in the presence of 
0.01–10 μg/mL of antibody. *P < 0.05; **P < 0.01
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(chLpMab- 7) [40] and human–rat chimeric anti- hPDPN 
antibodies such as NZ- 8 [36] and NZ- 12 [37]. Other 
groups have reported the development of human–mouse 
chimeric anti- hPDPN/hAggrus antibodies that were not 
cancer- specific [32, 33]. Because hPDPN is expressed in 
many normal organs such as the lung and kidney, 
non- CasMabs against hPDPN are not suitable for antibody- 
based molecular targeting therapy.
In this study, we used FUT8- KO CHO- S cells (PDIS- 5) 
to express afucosylated chLpMab- 2. Afucosylated antibodies 
are known to exhibit high ADCC [53]. Consistent with 
the literature, the ADCC of afucosylated chLpMab- 2 was 
3.4 times higher than that of fucosylated chLpMab- 2 (data 
not shown). In contrast, afucosylated chLpMab- 2 showed 
a lower CDC (Fig. 5B) than fucosylated chLpMab- 2 (data 
not shown). Gasdaska et al. have reported that the higher 
ADCC of afucosylated rituximab suggests an improvement 
in effectiveness and potency, however, its lower CDC may 
mitigate infusion toxicity [54]. They concluded that afu-
cosylated rituximab was clinically better than fucosylated 
rituximab. In contrast, Niwa et al. have reported that 
fucose depletion can provide a panel of IgGs (IgG1, IgG2, 
IgG3, and IgG4) with enhanced ADCC but that none of 
the IgGs affected CDC [53].
In our previous study, a human–mouse chimeric anti- 
hPDPN mAb showed CDC for antitumor activity in the 
absence of human NK cells in a mouse xenograft model 
[36]. In this study, chLpMab- 2 exhibited ADCC for anti-
tumor activity in the xenograft model with added NK 
cells [9]. Our results indicate that ADCC is important 
to induce the antitumor activity of anti- hPDPN CasMab 
in the xenograft model for two reasons: i) fucosylated 
chLpMab- 2, which was expressed in CHO- K1 cells, showed 
high CDC but failed to induce enough ADCC and anti-
tumor activity against hPDPN- expressing tumors (data 
not shown) and ii) afucosylated chLpMab- 2 did not show 
enough CDC in vitro (Fig. 5B) but exhibited higher ADCC 
in vitro (Fig. 5A) and antitumor activity against hPDPN- 
expressing tumors (Fig. 6).
Taken together, chLpMab- 2 may be useful as a novel 
antibody- based therapy against hPDPN- expressing tumors 
with no unexpected side effects.
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